1-3 of 3
Banmeet Anand
Close
Sort by
Journal Articles

Results from the Completed Dose Escalation Portion of the Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (MM)

Sumit Madan, Caitlin L. Costello, Brea Lipe, Andrew J. Cowan, Eva Medvedova, Jens Hillengass, P. Leif Bergsagel, Xavier Leleu, Cyrille Touzeau, Daniel Morillo, Albert Oriol, Raya Mawad, Henning Schade, Salomon Manier, Yifah Yaron, Banmeet Anand, Al-Ola Abdallah
Journal: Blood
Blood (2023) 142 (Supplement 1): 1012.
https://doi.org/10.1182/blood-2023-182345
Published: 2023
Journal Articles

AGS62P1, a Novel Anti-FLT3 Antibody Drug Conjugate, Employing Site Specific Conjugation, Demonstrates Preclinical Anti-Tumor Efficacy in AML Tumor and Patient Derived Xenografts

Nandini Rudra-Ganguly, PhD, Christine Lowe, Cyrus Virata, Monica Leavitt, Liqing Jin, MD, Brian Mendelsohn, PhD, Josh Snyder, Hector Aviña, Chunying Zhang, Deanna L Russell, Michael Mattie, PhD, Peng Yang, PhD, Baljinder Randhawa, Gao Liu, Faisal Malik, Misty Vest, Joseph D Abad, Christopher C Kemball, PhD, René Hubert, PhD, Sher Karki, PhD, Banmeet Anand, PhD, Zili An, MD, Jeanette Grant, PhD, John E. Dick, PhD, Fernando Doñate, PhD, Kendall Morrison, PhD, Pia Challita-Eid, PhD, Ingrid B Joseph, DVM, PhD, Daniel S. Pereira, PhD, David R. Stover, PhD
Journal: Blood
Blood (2015) 126 (23): 3806.
https://doi.org/10.1182/blood.V126.23.3806.3806
Published: 2015
Journal Articles

A Phase 1 Study of the Anti-CD37 Antibody-Drug Conjugate AGS67E in Advanced Lymphoid Malignancies. Interim Results

Ahmed Sawas, MD, Kerry J. Savage, MDMSc, Raymond Perez, MD, Ranjana H Advani, MD, Anna Butturini, MD, Jacqueline Lackey, Fabio Trave, MD, Banmeet Anand, PhD, Yao Huang, Leonard Reyno, MD, Owen A. O'Connor, MD
Journal: Blood
Blood (2015) 126 (23): 3976.
https://doi.org/10.1182/blood.V126.23.3976.3976
Published: 2015